An exploratory analysis of a canakinumab clinical trial has shown the interleukin 1β inhibitor may significantly reduce patients’ risk for gout flares. During the study, patients using canakinumab experienced this decreased risk, but the treatment did not change serum uric acid levels…
During a five-year trial of canakinumab, patients with systemic juvenile idiopathic arthritis taking canakinumab showed progress toward clinical remission and glucocorticoid tapering…
Recent research demonstrated that fibromyalgia patients have lower cerebral blood flow velocity variability than healthy controls, which may reflect impaired coordination of cerebral regulatory systems. This analysis may be a promising tool for characterizing fibromyalgia pathology and understanding health-related quality of life…
In a four-year study, patients with active psoriatic arthritis (PsA) experienced sustained improvement in PsA signs and symptoms on secukinumab…
Researchers say a study of individual antibody response to citrullinated and non-citrullinated proteins in sputum samples further supports the importance of the lung in early development of rheumatoid arthritis-related autoimmunity. Investigation of the fundamental mechanism that leads to antibody responses in rheumatoid arthritis is key to uncovering ways to predict and prevent the development of…
A study published in the May issue of Arthritis Care & Research may be the first to examine the long-term outcomes of childhood-onset lupus, otherwise known as pediatric systemic lupus erythematosus (SLE), a chronic, multisystem autoimmune disease with a highly variable clinical course. Previous studies examined cross-sectional views of damage accrued. According to the Childhood…
Indigenous communities in Latin America lack good healthcare—and often lack any healthcare—for musculoskeletal and rheumatic diseases.1 Global health initiatives tend to focus on infectious disease, despite the increasing rate of chronic diseases. In a survey of 6,155 individuals from eight indigenous communities, conducted by a team of Latin American investigators, the prevalence of these conditions…
Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating…
Psoriatic arthritis (PsA), like other inflammatory diseases, has been associated with increased incidence for and mortality from cardiovascular disease (CVD), the most common comorbidity leading to death in many conditions treated by rheumatologists. But beyond recognizing the burden of increased inflammation, the mechanisms behind this association are not well understood, says M. Elaine Husni, MD,…
“Don’t believe everything you think,” said Allan Lokos, the founder and guiding teacher of the Community Meditation Center located in New York City’s upper west side. These words may be especially important for those dealing with chronic pain, finds new multicenter research. The study, “Trajectories of Fear-Avoidance Beliefs on Physical Activity Over Two Years in…